

## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

### NOTICE OF ALLOWANCE AND ISSUE FEE DUE

HM12/091a

STEVEN P CALTRIDER ELI LILLY AND COMPANY LILLY CORPORATE CENTER PATENT DIVISION DC 1104 INDIANAPOLIS IN 46285

APPLICAT	TION NO. FILING		DATE	E TOTAL CLAIMS		EXAMINER AN	DATE MAILED		
	09/096	, 247	06/1	1/98	019	RUSSEL,	J	1654	09/14/
First Named Applicant	DEFELIPPIS,			38	USC 154(b)	0 Days.			

TITLE OF

STABLE INSULIN FORMULATIONS

ATTY'S DC	CKET NO.	CLASS-SUB	CLASS	BATCH NO.	APPLN. TYPE	SMALL	ENTITY	FEE DUE	DA	TE DUE
·	X-10	675	5	14-003.000	B60	UTILITY	. NO	\$12:	10.00	12/14/

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED.</u>

### HOW TO RESPOND TO THIS NOTICE:

- I. Review the SMALL ENTITY status shown above.
  If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:
  - A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
  - B. If the status is the same, pay the FEE DUE shown above.

If the SMALL ENTITY is shown as NO:

- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.
- II. Part B-Issue Fee Transmittal should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B Issue Fee Transmittal should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "4b" of Part B-Issue Fee Transmittal should be completed and an extra copy of the form should be submitted.
- III. All communications regarding this application must give application number and batch number.

  Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.



# UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FIRST NAMED APPLICANT ATTORNEY DOCKET NO. APPLICATION NUMBER FILING DATE DEFELIPPIS

HM12/0914

06/11/98 09/096,247

STEVEN P CALTRIDER ELI LILLY AND COMPANY LILLY CORPORATE CENTER PATENT DIVISION DC 1104 INDIANAPOLIS IN 46285

RUSSEL, J PAPER NUMBER ART UNIT

1654

09/14/99

DATE MAILED:

This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS

### **NOTICE OF ALLOWABILITY**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance and Issue Fee Due or other appropriate communication will be mailed in due course.
This communication is responsive to the anendnest filed 8-9-1997
The allowed claim(s) is/are 17-35
The drawings filed on are acceptable.
Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
received.
received in Application No. (Series Code/Serial Number)
received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:
Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" of this Office action. Failure to timely comply will result in ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).
Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
Applicant MUST submit NEW FORMAL DRAWINGS
because the originally filed drawings were declared by applicant to be informal.
including changes required by the Notice of Draftperson's Patent Drawing Review, PTO-948, attached hereto or to Paper No
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
including changes required by the attached Examiner's Amendment/Comment.
Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings.  The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson.
☐ Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.
Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included.
Attachment(s)
☐ Notice of References Cited, PTO-892
Information Disclosure Statement(s), PTO-1449, Paper No(s).
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948
□ Notice of Informal Patent Application, PTO-152
Interview Summary, PTO-413
Examiner's Amendment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material
Examiner's Statement of Reasons for Allowance

\*U.S. GPO: 1997-417-381/62707

Application/Control Number: 09/096,247

Art Unit: 1654

4<sup>at</sup> . 5

#### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

At originally-numbered claim 29 (re-numbered claim 13), line 1, the words "monomeric insulin analog" have been deleted.

Originally-numbered claim 29 (re-numbered claim 13) has been amended so that it is dependent upon originally-numbered claim 17 (re-numbered claim 1).

At originally-numbered claim 32 (re-numbered claim 16), line 1, "hypoglycemia" has been changed to "hyperglycemia".

At originally-numbered claim 35 (re-numbered claim 19), line 1, "hypoglycemia" has been changed to "hyperglycemia".

Authorization for this examiner's amendment was given in a telephone interview with Attorney Mark J. Stewart on September 3, 1999.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey E. Russel at telephone number (703) 308-3975. The examiner can normally be reached on Monday-Thursday from 8:30 A.M. to 6:00 P.M. The examiner can also be reached on alternate Fridays.

Application/Control Number: 09/096,247 Page 3

Art Unit: 1654

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Michael Woodward can be reached at (703) 308-4028. The fax number for Art Unit 1654 for formal communications is (703) 305-3014; for informal communications such as proposed amendments, the fax number (703) 305-7401 can be used. The telephone number for the Technology Center 1 receptionist is (703) 308-0196.

Jeffrey E. Russel

**Primary Patent Examiner** 

Art Unit 1654

**JRussel** 

September 3, 1999